Literature DB >> 10852539

Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.

D M Holtzman1, A M Fagan, B Mackey, T Tenkova, L Sartorius, S M Paul, K Bales, K H Ashe, M C Irizarry, B T Hyman.   

Abstract

The epsilon4 allele of apolipoprotein E (ApoE) is an important genetic risk factor for Alzheimer's disease (AD). Increasing evidence suggests that this association may be linked to the ability of ApoE to interact with the amyloid-beta (Abeta) peptide and influence its concentration and structure. To determine the effect of ApoE on Abeta and other AD pathology in vivo, we used APPsw transgenic mice and ApoE knockout (-/-) mice to generate APPsw animals that carried two (ApoE +/+), one (ApoE +/-), or no copies (ApoE -/-) of the normal mouse ApoE gene. At 12 months of age, Abeta deposition was present in the cortex and hippocampus and was also prominent within leptomeningeal and cortical blood vessels of all APPsw ApoE +/+ mice. Importantly, although Abeta deposition still occurred in APPsw ApoE -/- mice, no fibrillar Abeta deposits were detected in the brain parenchyma or cerebrovasculature. There was also no neuritic degeneration associated with Abeta deposition in the absence of ApoE. These data demonstrate that ApoE facilitates the formation of both neuritic and cerebrovascular plaques, which are pathological hallmarks of AD and cerebral amyloid angiopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852539

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  118 in total

1.  Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy.

Authors:  R Christie; M Yamada; M Moskowitz; B Hyman
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 3.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Prediction of S-glutathionylated proteins progression in Alzheimer's transgenic mouse model using principle component analysis.

Authors:  Cheng Zhang; Ching-Chang Kuo; Alan W L Chiu; June Feng
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  Intracranial volume and dementia: some evidence in support of the cerebral reserve hypothesis.

Authors:  D F Tate; E S Neeley; M C Norton; J T Tschanz; M J Miller; L Wolfson; C Hulette; C Leslie; K A Welsh-Bohmer; B Plassman; Erin D Bigler
Journal:  Brain Res       Date:  2010-12-21       Impact factor: 3.252

6.  APOE ε variants increase risk of warfarin-related intracerebral hemorrhage.

Authors:  Guido J Falcone; Farid Radmanesh; H Bart Brouwers; Thomas W K Battey; William J Devan; Valerie Valant; Miriam R Raffeld; Lennox P Chitsike; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; Magdy Selim; James F Meschia; Devin L Brown; Bradford B Worrall; Scott L Silliman; David L Tirschwell; Matthew L Flaherty; Sharyl R Martini; Ranjan Deka; Alessandro Biffi; Peter Kraft; Daniel Woo; Jonathan Rosand; Christopher D Anderson
Journal:  Neurology       Date:  2014-08-22       Impact factor: 9.910

7.  Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition.

Authors:  Byung Hee Han; Meng-Liang Zhou; Fadi Abousaleh; Robert P Brendza; Hans H Dietrich; Jessica Koenigsknecht-Talboo; John R Cirrito; Eric Milner; David M Holtzman; Gregory J Zipfel
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

8.  Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people.

Authors:  D A Bennett; J A Schneider; R S Wilson; J L Bienias; E Berry-Kravis; S E Arnold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

9.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

Authors:  Jungsu Kim; Joseph M Castellano; Hong Jiang; Jacob M Basak; Maia Parsadanian; Vi Pham; Stephanie M Mason; Steven M Paul; David M Holtzman
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

Review 10.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.